A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

Phase 2CompletedNCT00666900

Dow Pharmaceutical Sciences366 enrolled

Overview

The purpose of this study is to assess the safety and effectiveness of IDP-107 in treating patients with acne vulgaris.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

366

Conditions

Acne Vulgaris

Interventions

Low Strength IDP-107DRUG

Once a day for 12 weeks

High Strength IDP-107DRUG

Once a day for 12 weeks

Placebo ComparatorDRUG

Once a day for 12 weeks

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Presence of inflammatory and non-inflammatory lesions Exclusion Criteria: * Dermatological conditions of the face that could interfere with clinical evaluations * Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study

Locations (25)

Burke Pharmaceutical Research

Outcomes

Primary Outcomes

Change from baseline in the number of inflammatory lesions

Time frame: 12 weeks

Improvement from baseline in global severity

Time frame: 12 weeks

Secondary Outcomes

Change from baseline in the number of non-inflammatory lesions

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.